AN OVERVIEW OF TRANSDERMAL DELIVERY SYSTEM

  • Reshmi Jayaprakash Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham University, Amrita University, AIMS Healthcare Campus, Ponekkara P.O., Kochi, Kerala, India.
  • Jahnara Hameed Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham University, Amrita University, AIMS Healthcare Campus, Ponekkara P.O., Kochi, Kerala, India.
  • Anupriya Anupriya Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham University, Amrita University, AIMS Healthcare Campus, Ponekkara P.O., Kochi, Kerala, India.

Abstract

Recently, most widely using conventional dosage form such as tablet, capsules, and injections but due to some case we are preferable to choose transdermal drug delivery system (TDDS) because conventional oral dosage form undergo first pass metabolism. In TDDS, skin is the effective medium for the penetration of drug into systemic circulation. This system required very low dose for the effective result or action. One of the major disadvantages of TDDS is penetration rate is very low through the stratum corneum. Nowadays, different types of skin penetration enhancement techniques are used for increasing the penetration. These types of techniques can be also increase the bioavailability. The patients have more preferable to choose this type of drug delivery system because it has more advantages than conventional dosage form. This article is discuses about the anatomy and physiology of skin and its drug penetration capacity, polymers used in transdermal drug delivery and different types of TDDS.

Keywords: Transdermal drug delivery, Skin, Polymers, Enhancement techniques.

References

1. Ritesh K, Anil P. Modified transdermal technology: Breaking the barriers of drug permeation via the skin. Trop J Pharm Res 2007;6(1):633-44.
2. Barry B. Transdermal drug delivery. In: Aulton EM, editor. Pharmaceutics: The Science of Dosage form Design. 2nd ed. New York: Harcourt Publishers; 2002. p. 499.
3. Kumar P, Sankar C, Mishra B. Delivery of macromolecules through skin. Indian Pharm 2004;5(3):7-17.
4. Finnin CB. Transdermal drug delivery-what to expect in the near future. Bussiness Briefing: Pharm Tech. London: World Market Research Centre; 2003. p. 192-3.
5. Nikhil S, Geta A, Rana AC, Zulfiqar A, Dinesh K. A review: Transdermal drug delivery system: A Tool for novel drug delivery system. Int J Drug Dev Res 2011;3(3):70-84.
6. Tortora GJ, Bryan D. Principles of Anatomy and Physiology. 13th ed., Vol. 1. New York: J. Wiley; 2011. p. 154-61.
7. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and Advance. 1st ed. New Delhi: Vallabh Prakashan; 2002. p. 411-77.
8. Heather AE. Transdermal drug delivery: Penetration enhancement techniques. Curr Drug Deliv 2005;2(1):23-33.
9. Birger B, Bente S, Carsten UN. Passive Diffusion of Drug Substance: The Concepts of Flux and Permeability. Available from: http://www.pharmpress.com/files/docs/molbiopharmaceutics.sample.pdf.
10. Subrahmanyam CV. Text book of Physical Pharmaceutics. New Delhi: Vallabh Prakashan; 2010. p. 110-26.
11. Rakesh R, Anoop KR. Formulation and optimization of nano-sized ethosomes for enhanced transdermal delivery of cromolyn sodium. J Pharm Bioallied Sci 2012;4(4):333-40.
12. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56(5):603-18.
13. Murali S, Nair SC, Priya A. Drug delivery research: Current status and future prospects. Int J Pharm Sci Rev Res 2016;40(1):94-9.
14. Tsai JC, Guy RH, Thornfeldt CR, Gao WN, Feingold KR, Elias PM. Metabolic approaches to enhance transdermal drug delivery 1. Effect of lipid synthesis inhibitors. J Pharm Sci 1996;85(6):643-8.
15. Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. Int J Pharm 2008;364(2):227-36.
16. Banga AK. Transdermal and Intradermal Delivery of Therapeutic Agents: Application of Physical Technology. Boca Raton, FL: RC Press; 2011.
17. Wokovich AM, Prodduturi S, Doub WH, Hussain AS, Buhse LF. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur J Pharm Biopharm 2006;64(1):1-8.
18. Debjit B, Pusupoleti KR, Duraivel S, Sampath K. Recent approaches in transdermal drug delivery system. J Pharm Innov 2013;2(3):99-107.
19. Keith AD. Polymer matrix consideration for transdermal device. Drug Dev Ind Pharm 1983;9:602-25.
20. Cornwell PA, Barry BW. Sesquiterpene components of volatile oils as skin penetration enhancers for the hydrophilic permeant 5-fluorouracil. J Pharm Pharmacol 1994; 46: 261-269.
21. Qvist MH, Hoeck U, Kreilgaard B, Madsen F, Frokjaer S. Release of chemical permeation enhancers from drug-in-adhesive transdermal patches. Int J Pharm 2002;231(2):253-63.
22. Minghetti P, Cilurzo F, Montanari L. Evaluation of adhesive properties of patches based on acrylic matrices. Drug Dev Ind Pharm 1999;25(1):1-6.
23. Archana KG. Transdermal drug delivery system: Formulation aspects and evaluation. J Pharm Sci 2013;1(1):1-10.
24. Sugibayashi K, Morimoto Y. Polymers for transdermal drug delivery system. J Control Release 1994;29:177-85.
25. Arti K, Ajit KY, Sunil S, Henendra G, Haribansh NS, Anamika S, et al. Theoretical aspects of transdermal drug delivery system. Bull Pharm Res 2013;3(2):78-89.
26. Bromberg L. Cross-linked ploy (ethylene glycol) networks as reservoirs for protein delivery. J Appl Polym Sci 1996;59:459-66.
27. Sateesh K, Vinod N, Ramesh P. Polymer in transdermal drug delivery system. Pharm Technol 2002;26:62-80.
28. Repka MA, McGinity JW. Bioadhesive properties of hydroxypropylcellulose topical film produced by hot-melt extrusion. J Control Release 2001;70(3):341-51.
29. Gupta SK, Southam M, Gale R, Hwang SS. System functionality and physicochemical model of fentanyl transdermal system. J Pain Symptom Manage 1992;7 3 Suppl: S17-26.
30. Fauth C, Wiedersberg S, Neubert RH, Dittgen M. Adhesive backing foil interactions affecting the elasticity, adhesion strength of laminates, and how to interpret these properties of branded transdermal patches. Drug Dev Ind Pharm 2002;28(10):1251-9.
31. Ashburn MA, Ogden LL, Zhang J, Love G, Basta SV. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J Pain 2003;4(6):291-7. 32. Harrison LL, Harari D. An evaluation of bioequivalence of two 7-day 17 beta-estradiol transdermal delivery systems by anatomical site. J Clin Pharmacol 2002;42(10):1134-41.
33. Larsen RH, Nielsen F, Sørensen JA, Nielsen JB. Dermal penetration of fentanyl: Inter-and intraindividual variations. Pharmacol Toxicol 2003;93:244-8.
34. Wick KA, Wick SM, Hawkinson RW, Holtzman JL. Adhesion-to-skin performance of a new transdermal nitroglycerin adhesive patch. Clin Ther 1989;11(5):417-24.
35. Finnin BC, Morgan TM. Transdermal penetration, application, limitation and potential. J Pharm Sci 1999;88(10):955-8.
36. Zhou Y. Fine element analysis of diffusional drug release from complex matrix system. J Control Release 1997;49(2-3):277-88.
37. Rajesh N, Siddaramaiah, Gowda DV, Somashekar CN. Formulation and evaluation of biopolymer based transdermal drug delivery. Int J Pharm Pharm Sci 2010;2(2):142-7.
38. Dey S, Malgope A. Preparation of carvedilol transdermal patch and the effect of propylene glycol on permeation. Int J Pharm Pharm Sci 2010;2 Suppl 1:137-43.
Statistics
231 Views | 314 Downloads
Citatons
How to Cite
Jayaprakash, R., J. Hameed, and A. Anupriya. “AN OVERVIEW OF TRANSDERMAL DELIVERY SYSTEM”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 10, Sept. 2017, pp. 36-40, doi:10.22159/ajpcr.2017.v10i10.19909.
Section
Review Article(s)